Event in Progress:
Discover the latest content that has just been published on Research Tree
Bristol-Myers has continued its efforts towards expanding its new product range, in-line franchises, pipeline, and carried out critical business growth initiatives. The company’s revenues for the second quarter reached approximately $11.9 billion, up 5% from the same period last year and surpassed Wall Street expectations. This result was fuelled by their in-line and new product portfolio's 16% solid growth, which more than made up for their recent LOEs. The company also lays the groundwork for
Companies: Bristol-Myers Squibb Company (BMY:NYS)Bloomsbury Publishing Plc (BMY:LON)
Bristol-Myers Squibb Company had a strong start to 2022 with the U.S. FDA having approved the Camzyos or mavacanten, a first-class medicine for symptomatic obstructive HCM disease. The company also received approval for Opdualag to treat unresectable or metastatic melanoma and thy have started a pivotal study for colorectal cancer.. In March, U.S. FDA also approved Opdivo as the foremost I-O agent for treating the early stages of lung cancer whereas in Europe, Breyanzi has received regulatory ap
Bristol-Myers Squibb has a decent set of financials and their recent performance is fueled by core drugs, Eliquis and Opdivo, as well as continued demand growth for their new products. The company's launch of Zeposia in the U.S. for ulcerative colitis has progressed smoothly and they recently received European approval for the same during the past quarter. The management is also expanding their cardiovascular portfolio and presented exciting data for Milvexian at AHA. They see it as the next-gen
Bristol-Myers Squibb had another strong quarter with strong results in their ongoing business, fueled by Eliquis and Opdivo, as well as continued demand growth for their new products. In the United States, the launch of Zeposia for ulcerative colitis is going well, and the company received European approval during the quarter. They are also expanding their cardiovascular portfolio and presented exciting data for Milvexian at AHA. They see it as the next-generation anti-thrombotic with a non-risk
Bristol-Myers Squibb had a robust third quarter, with significant sales growth fueled by strong commercial execution and pipeline advancement. They performed well in their commercial units which drove demand growth for their launch products and delivered a strong performance of their In-Line products, including Opdivo, Revlimid, and Eliquis. In the third quarter, the company advanced its third I-O mechanism with the fixed dose of Relatlimab plus Nivolumab approved for priority review in the U.S.
Bristol-Myers Squibb had another strong quarter with a particularly strong performance of its oncology drugs, Revlimid and Opdivo. After the Celgene acquisition, the pharmaceutical major’s largest chunk of revenues comes from these 2 cancer treatments and the blood thinning drug, Eliquis, which might gain excellent momentum in the coming quarters given the increasing application of blood thinners in Covid-19 treatments. Eliquis already grew by a staggering 29% in the last quarter and contributed
The cancer burden is growing globally. Each year >18 million people are diagnosed, nearly 10 million die and the estimated economic cost exceeds $1 trillion. From early diagnosis to late-stage disease, cancer care often involves inappropriate or unnecessary interventions that drive costs but provide limited clinical benefit. Coupled with an increased understanding of cancer biology and rapid technological advances, this has been driving momentum for precision medicine, leading to patient and soc
Companies: VSC ABT ABBV AFMD A GOOGL AMGN AZN BCART BMY EKTAB EXAS GSK ILMN IPH ISRG IBAB JNJ MDXH MDG1 MDT MRK MYGN NSTG NOVN OCX PFE RAYB ROG SAN SGEN TMO TNG VCYT VNRX XNCR ECX IMM QGEN
goetzpartners securities Limited
Research Tree provides access to ongoing research coverage, media content and regulatory news on Bristol-Myers Squibb Company.
We currently have 6 research reports from 2
VLG has delivered a pleasing and reassuring H1 result against a challenging backdrop. The recent acquisitions are performing strongly and it has been able to mitigate a lot of the recent incremental cost/inflation headwinds. Trading so far in H2 is slightly ahead of plan and it has a very strong order book which will lead to increased H2 weighting. Confidence in EBITDA forecasts is therefore high. We have, however, reduced our PBT/EPS forecasts on the back of higher D&A (non-cash) than expected.
Companies: Venture Life Group Plc
Singer Capital Markets
Oncimmune has released results for the 12m period to May-22, ahead of its changed year and to August. These results reflect a period of investment into the commercial team for ImmunoINSIGHTS and increased penetration into the Top 15 global pharma customers, where a number of MSAs have been signed. These are expected to translate into faster contract wins and management reports a current weighted value pipeline of £11.0m across the business, providing increased revenue visibility. Cost savings in
Companies: Oncimmune Holdings Plc
Companies: Warpaint London PLC
Belluscura has made very significant progress in technology, manufacturing and sales in the year to date and remains strongly positioned to achieve considerable scale next year.
Companies: Belluscura PLC
Trading momentum has been sustained in early Q3, triggering a 3rd upgrade YTD. There is clear evidence the growth strategy is bearing fruit. Distribution gains are increasing brand reach both in the UK and overseas. This appears to be an ideal time for its on-trend value-for-money proposition to gain traction in its key channels, potentially with counter-cyclical characteristics as consumers start trading down. After a further pull-back (YTD now -29%), valuation is out of synch with its growth t
OptiBiotix has launched its GoFigure weight management range in India through its commercial partner Apollo Hospitals (Apollo). Apollo owns and operates the largest pharmacy network across India and will initially stock the GoFigure range in key stores in major Indian cities, as well as online. Apollo is one of three large partners which entered commercial agreements with OptiBiotix in late-2021. The launch demonstrates OptiBiotix' strategic shift towards selling a greater proportion of finished
Companies: OptiBiotix Health PLC
Trinity Delta view: The positive outcome of the critical US FM71 longer-term study for MED3000 removes clinical uncertainty, shifting the focus to regulatory and commercial execution. The MED3000 regulatory package for the OTC treatment of erectile dysfunction, including data from FM57, is expected to be submitted to the FDA by end-September and following five pre-submission meetings, a rapid review for a decision by end Q123 is hoped for. In parallel, the search for a US commercial partner has
Companies: Futura Medical plc
H1 saw a continued recovery in revenues, which are now comfortably back above pre-pandemic levels, despite some territories lagging. The group’s sustainability and cost-saving messaging looks to be increasingly resonating as health systems globally look to address the twin challenges of elective recovery and environmental impact. Some inflationary and supply chain issues have been experienced, although these are expected to ease in H2 as mitigations take effect. We make no change to our forecast
Companies: Surgical Innovations Group plc
Companies: NTQ MORE POLB BILN
Dish of the day
No joiners today.
Leavers: No leavers today.
What’s cooking in the IPO kitchen?**
Independent Living REIT plc, intends to float on the Premium Segment of the Main Market. The Company's investment objective is to address the shortage of high-quality supported housing, delivering capital growth and inflation-linked income returns for its investors whilst providing a fair deal for society through savings for the UK taxpayer, and improved outcomes for residents. Raising £150
Companies: W7L WAND SUN KWS KIBO LBG SDX
Following ReNeuron’s strategic review and change of management, the company has refocused on the exploitation of its exosome platform. We have likewise focussed our research on the potential for, and value of, ReNeuron’s exosomes. In this note, we do not dwell on the past but explore the potential for ReNeuron’s exosomes and why they may be the answer to pressing drug delivery questions. One of its previous products – now under the control of a partner – remains as an upside to our valuation.
Companies: ReNeuron Group plc
Venture Life has published its interim results for the 6-months to June 22, which show profits slightly ahead of the previous trading update. Revenues grew 36% in the period to £18.9m, while both gross and adjusted EBITDA margins improved strongly, 5.0 and 3.6 percentage points, respectively. Growth was driven by recent acquisitions, with new distribution deals and product launches through the period. Performance has continued into H2/22, with further deals signed and trading in-line with expect
Interims show a strong underlying performance with “core established” revenues +11.5% in the period. As previously discussed, the business is in the process of transitioning away from Covid-related work and implementing the growth strategy of the new management team. Initial indications are positive and investment plans are on track, which should set the business up for strong growth in FY23 and beyond. We make no material changes to forecasts and continue to see substantial potential upside on
Companies: EKF Diagnostics Holdings plc
Deltex Medical Group (Deltex Medical) develops and markets a “best in class” haemodynamic monitoring system using Doppler ultrasound technology. Its TrueVue ODM+ platform is the world’s first fluid management and cardiac output monitoring technology which directly measures both blood flow velocity and blood pressure. With access to some international markets back to pre-COVID levels, the need to reduce elective surgery backlogs, the launch of a new monitor later this year, including the first it
Companies: Deltex Medical Group plc
Merck continues to perform pretty well in the last quarter and delivered another all-around beat while continuing to bid on long-term growth. During the quarter, it achieved robust bottom and top-line growth and has made some additional vital clinical advancements in its pipelines. The exceptional performance in the quarter was led by robust growth of main products, which include Bridion, Gardasil, and Keytruda. For pediatric cases, Vaxneuvance has received an extended approval from the FDA. The
Companies: Merck & Co., Inc. (MRK:NYS)Merck KGaA (MRK:ETR)